Your browser does not support iframes.
N&O 100
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Celgene Corp
(NQ:
CELG
)
120.24
USD
+2.54 (+2.16%)
Official Closing Price
/ Updated:
4:00 PM EDT, Jun 18, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
1,827,375
Open
118.28
Bid (Size)
120.19 (100)
Ask (Size)
120.24 (500)
Prev. Close
117.70
Today's Range
117.72 - 120.45
52wk Range
58.53 - 131.82
Shares Outstanding
417,122,477
Dividend Yield
N/A
Top News
More News
Advanced Treatment Methods, Significant Study Results, Conferences, and Final Study Data Releases - Research Report on Amgen, Celgene, Vertex Pharmaceuticals, MannKind, and Peregrine Pharmaceuticals
Today 8:00 EDT
Editor Note: For more information about this release, please scroll to bottom
Read More
from
PR Newswire
Trade of the Day: Celgene (CELG)
June 17, 2013
Read More
category
NASDAQ:CELG
from
InvestorPlace - Latest Headlines
More News
Read More
Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients with Rare Form of Blood Disease
June 17, 2013
from
Business Wire News Releases
Celgene Int'l (CELG) Apremilast Hits Primary, Secondary Endpoints in BD Phase II
June 14, 2013
from
StreetInsider.com News Articles
Celgene Announces Statistical Significance for Primary, Secondary Endpoints in Phase II Trial in Patients with Behçet's Disease
June 14, 2013
category
Contracts
,
Benzinga
,
Guidance
, and 2 more.
from
Latest Articles from Benzinga.com
Oral Apremilast Achieves Statistical Significance for Primary and Secondary Endpoints in a Phase II Trial in Patients with Behçet’s Disease
June 14, 2013
from
Business Wire News Releases
Upgrade Alert for Celgene (CELG)
June 13, 2013
from
Comtex SmarTrend® News Briefs
Stock Upgrades: Bulls Run on Adidas AG
June 13, 2013
category
CELG
,
GILD
from
Minyanville Headlines
Argus Upgrades Celgene (CELG) to Buy
June 13, 2013
from
StreetInsider.com News Articles
Data from Phase III Randomized Controlled Study (PALACE 3) of Apremilast in Psoriatic Arthritis Presented at EULAR
June 13, 2013
from
Business Wire News Releases
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.